| Literature DB >> 23015789 |
Maaike Hoekstra1, Christine L Mummery, Arthur A M Wilde, Connie R Bezzina, Arie O Verkerk.
Abstract
Cardiac arrhythmias are a major cause of morbidity and mortality. In younger patients, the majority of sudden cardiac deaths have an underlying Mendelian genetic cause. Over the last 15 years, enormous progress has been made in identifying the distinct clinical phenotypes and in studying the basic cellular and genetic mechanisms associated with the primary Mendelian (monogenic) arrhythmia syndromes. Investigation of the electrophysiological consequences of an ion channel mutation is ideally done in the native cardiomyocyte (CM) environment. However, the majority of such studies so far have relied on heterologous expression systems in which single ion channel genes are expressed in non-cardiac cells. In some cases, transgenic mouse models have been generated, but these also have significant shortcomings, primarily related to species differences. The discovery that somatic cells can be reprogrammed to pluripotency as induced pluripotent stem cells (iPSC) has generated much interest since it presents an opportunity to generate patient- and disease-specific cell lines from which normal and diseased human CMs can be obtained These genetically diverse human model systems can be studied in vitro and used to decipher mechanisms of disease and identify strategies and reagents for new therapies. Here, we review the present state of the art with respect to cardiac disease models already generated using IPSC technology and which have been (partially) characterized. Human iPSC (hiPSC) models have been described for the cardiac arrhythmia syndromes, including LQT1, LQT2, LQT3-Brugada Syndrome, LQT8/Timothy syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT). In most cases, the hiPSC-derived cardiomyoctes recapitulate the disease phenotype and have already provided opportunities for novel insight into cardiac pathophysiology. It is expected that the lines will be useful in the development of pharmacological agents for the management of these disorders.Entities:
Keywords: cardiac arrhythmia syndromes; cardiomyocytes; electrophysiology; heart; human; iPS; induced pluripotent stem cells
Year: 2012 PMID: 23015789 PMCID: PMC3449331 DOI: 10.3389/fphys.2012.00346
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Action potential characteristics in hiPSC-CM and human ventricular cardiomyocytes.
| iPSC-CM V IMR90C4 | 43.8 ± 2.7 | 320.1 ± 17 | 40.5 ± 4.6 | 87.7 ± 2.6 | −63.5 ± 1.7 | 37°C, me LJP: corr. | Zhang et al., |
| iPSC-CM V ForeskinC1 | 44.2 ± 3.5 | 312.5 ± 11.2 | 27.2 ± 3.7 | 87.9 ± 2.4 | −63.3 ± 1.5 | 37°C, me LJP: corr. | Zhang et al., |
| iPSC-CM V | 68.2 ± 2.7 | 381.3 ± 35.3 | 9 ± 0.2 | 107.8 ± 2.1 | −63.5 ± 2.1 | 35°C, wc LJP:nk | Moretti et al., |
| iPSC-CM V | 72 ± 1.2 | 314.4 ± 17.6 | 26.8 ± 6.3 | 113.2 ± 2.4 | −63.4 ± 1.3 | 36°C, pp LJP: nk | Lahti et al., |
| iPSC-CM V | 35.5 ± 2.1 | 414.7 ± 21.8 | 27.8 ± 4.8 | 101.5 ± 2.5 | −75.6 ± 1.2 | 35–37°C pp, LJP: nk | Ma et al., |
| iPSC-CM V | 28 ± 5 | 495 ± 36 | 9.5 ± 1.8 | 109 ± 3 | −57 ± 1 | 32°C, wc LJP: nk | Itzhaki et al., |
| iPSC-CM | 60 | 173.5 ± 12.2 | 115.7 ± 18.4 | 106 ± 3.2 | −72.4 ± 0.9 | 37°C, pp LJP: corr | Davis et al., |
| hESC-CM V | 47.1 ± 23.3 | 247.2 ± 66.7 | 13.2 ± 6.2 | 85.4 ± 9.3 | −53.9 ± 8.6 | 37°C, me LJP: nk | He et al., |
| hESC-CM V | 285.8 ± 52.6 | 11.4 ± 2.8 | 86.8 ± 52.6 | −62.3 ± 8.6 | rt, wc LJP: nk | Zhang et al., | |
| VM | 50 | 213 ± 7 | 215 ± 33 | 106.7 ± 1.4 | −81.8 ± 3.3 | 37°C, wc LJP: nk | Magyar et al., |
| VM endo | 60 | 330 ± 16 | 234 ± 28 | 105 ± 2 | −87.1 ± 1 | 37°C, wc LJP: nk | Drouin et al., |
| VM epi | 60 | 351 ± 14 | 228 ± 11 | 104 ± 2 | −86 ± 1 | 37°C, wc LJP: nk | Drouin et al., |
iPS-CM V, iPS-CM of ventricular-like phenotype; iPS-CM ns, not specified to action potential type; VM, native human ventricular myocyte; endo, endocardial; epi, epicardial; BPM, beats per minute; APD90, action potential duration at 90% of repolarization; dV/dtmax, maximal upstroke velocity; APA, action potential amplitude; MDP, maximum diastolic potential; RMP, resting membrane potential;
, non spontaneous beating cells;
hESC-CM V, hESC-CM of ventricular-like phenotype; me, micro electrode; wc, whole cell patch-clamp configuration; ljp: corr, corrected for liquid junction potential; ljp:nk, not known if corrected for liquid junction potential; rt, room temperature.
Figure 1(A) Schematic representation of a human ventricular action potential (top panel). Numbers denote the different phases of the ventricular action potential. The dashed line represents phase 4 depolarization normally present in cells from the conduction system and not in ventricular CMs. Underlying ionic membrane currents and their schematic time course are depicted below. (B) Schematic representation of an early afterdepolarization (EAD) and its underlying mechanism. (C) Schematic representation of a delayed afterdepolarization (DAD) and its underlying mechanism. INa, Na+ current; ICa,L, L-type Ca2+ current; ICa,T, T-type Ca2+ current; Ito1, transient outward current type 1; ICl(Ca), Ca2+ activated Cl− current, also called Ito2; IKur, ultra rapid component of the delayed rectifier K+ current, IKr, rapid component of the delayed rectifier K+ current; IKs, slow component of the delayed rectifier K+ current; IK1, inward rectifier K+ current; If, funny current; INCX, Na+/Ca2+ exchange current.
Ion channel current and gating properties in hiPS-CM and human cardiomyocytes.
| INa | iPS-CM | −216.7 ± 18.7 | −34.1 | 5.9 | −72.1 | −5.7 | 35–37°C wc, LJP: nk | Ma et al., |
| iPS-CM | ~280 (Figure 8C) | ~ −42 (Figure 8D) | 37°C, pp LJP: nc | Davis et al., | ||||
| hESC-CM | −72 ± 21 | −34 | 5.7 | −78 | −4.6 | 20°C, wc LJP: nk | Jonsson et al., | |
| VM | −20.2 ± 2.2 | −42.4 ± 3.0 | 6.3 ± 0.5 | −100 ± 2.1 | −6.3 ± 0.5 | 17°C, wc LJP: nk | Sakakibara et al., | |
| ICa,L | iPS-CM | −17.1 ± 1.7 | −14.9 | 6.6 | −29.1 | −4.9 | 35–37°C wc, LJP: nk | Ma et al., |
| iPS-CM | −3.3 | ~ −45 (Figure 2E) | 25°C, wc LJP: nk | Yazawa et al., | ||||
| hESC-CM | −4.3 ± 0.6 | −12 | 5.5 | 37°C, wc LJP: nk | Jonsson et al., | |||
| VM | −10.2 ± 0.6 | −4.7 ± 0.7 | 3.7 ± 0.3 | −19.3 ± 1.2 | −3.45 ± 0.6 | 37°C, wc LJP: nk | Magyar et al., | |
| VM | −3.8 ± 0.5 | −4.2 ± 0.8 | 7 ± 0.3 | −23.5 ± 1.4 | −5.5 ± 1.4 | 21–23°C wc, LJP: nk | Mewes and Ravens, | |
| AM | −2.2 ± 0.3 | −12.1 ± 1.3 | 5.8 ± 0.4 | −26.8 ± 1.3 | −5.7 ± 0.2 | 21–23°C wc, LJP: nk | Mewes and Ravens, | |
| Ito1 | iPS-CM | ~2.4 (Figure 6D) | 35–37°C wc, LJP: nk | Ma et al., | ||||
| iPS-CM | ~30 (Suppl. Figure 10A) | 35°C, wc LJP: nk | Moretti et al., | |||||
| hESC-CM | 6.0 ± 0.9 | 37°C, wc LJP: nk | Sartiani et al., | |||||
| VM endo | ~5 (Figure 2B) | 29.1 ± 1.2 | 12.9 ± 1.1 | −17.6 ± 1.0 | −8.9 ± 0.9 | 35°C, wc LJP: nk | Nabäuer et al., | |
| VM epi | ~16 (Figure 2A) | 32.0 ± 1.11 | 14.9 ± 0.8 | −9.5 ± 0.38 | −5.1 ± 0.4 | 35°C, wc LJP: nk | Nabäuer et al., | |
| VM endo | 2.3 ± 0.3 | 23.1 ± 4.2 | 12.9 ± 0.8 | −25.3 ± 3.0 | −4.7 ± 0.8 | 20–22°C wc, LJP: nk | Wettwer et al., | |
| VM epi | 7.9 ± 0.7 | 15.4 ± 0.7 | 9.7 ± 1.6 | −31.9 ± 1.5 | −4.6 ± 0.2 | 20–22°C wc, LJP: nk | Wettwer et al., | |
| IKr | iPS-CM | 0.95 ± 0.02 | −22.7 | 4.9 | 35–37°C wc, LJP: nk | Ma et al., | ||
| iPS-CM | ~1.9 (Figure 4A) | 35°C, wc LJP: nk | Moretti et al., | |||||
| iPS-CM | ~1.9 (Figure 5C) | 36°C, pp LJP: nk | Lahti et al., | |||||
| iPS-CM | ~0.55 (Figure 3D) | 32°C, wc LJP: nk | Itzhaki et al., | |||||
| hESC-CM | −11.5 ± 1.8 | 37°C, wc LJP: nk | Jonsson et al., | |||||
| VM | ~0.25 (Figure 1C) | −5.74 | 5.63 | 37°C, wc LJP: nk | Iost et al., | |||
| VM | 0.31 ± 0.02 | 37°C, wc LJP: nk | Magyar et al., | |||||
| IKs | iPS-CM | 0.31 ± 0.09 | 35–37°C wc, LJP: nk | Ma et al., | ||||
| iPS-CM | ~2.5 (Figure 4A) | 35°C, wc LJP: nk | Moretti et al., | |||||
| hESC-CM | 0.65 ± 0.12 | 37°C, wc LJP: nk | Jonsson et al., | |||||
| VM | 0.18 | 37°C, wc LJP: nk | Virag et al., | |||||
| IK1 | iPS-CM | ~ −3.8 (Figure 6C) | 35–37°C wc, LJP: nk | Ma et al., | ||||
| hESC-CM | −2.67 ± 0.3 | 37°C, wc LJP: nk | Jonsson et al., | |||||
| VM | ~ −10 (Figure 3B) | 37°C, wc LJP: nk | Magyar et al., | |||||
| If | iPS-CM | −4.1 ± 0.3 | −84.6 | 8.8 | 35–37°C wc, LJP: nk | Ma et al., | ||
| hESC-CM | −10 ± 1.1 | −74 | 4.5 | 37°C, wc LJP: nk | Jonsson et al., | |||
| VM | −1.18 ± 0.21 | −111 ± 0.06 | 22°C, wc LJP: nk | Hoppe et al., | ||||
| SAN | ~ −8.0 (Figure 3B) | −96.9 ± 2.7 | 8.8 ± 0.5 | 36°C, wc LJP: corr | Verkerk et al., |
VM, native human ventricular myocyte; AM, native human atrial myocyte; endo, endocardial; epi, epicardial; SAN; native sinoatrial node myocyte; ~, estimated from figure. INa, Na+ current; ICa,L, L-type Ca2+ current; Ito1, Transient outward current type 1; IKr, rapid compontent of the delayed rectifier K+ current; IKs, slow component of the delayed rectifier K+ current; IK1, inward rectifier K+ current; If, funny current; V1/2 act, potential of half maximal activation; k act, slope factor of activation curve; V1/2 inact, potential of half maximal inactivation; k inact, slope factor of inactivation curve hESC-CM; V, hESC-CM of ventricular-like phenotype; wc, whole cell patch-clamp configuration; ljp: corr, corrected for liquid junction potential; ljp: nk, not known if corrected for liquid junction potential, ljp: nc, not corrected for liquid junction potential.